Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas Files Veozah in Japan for Menopausal VMS
Astellas Pharma has filed its oral nonhormonal agent fezolinetant in Japan for the treatment of vasomotor symptoms (VMS) associated with menopause.The drug is a selective neurokinin 3 (NK3) receptor antagonist and is already marketed in the US under the Veozah…
To read the full story
Related Article
- Veozah Hits Primary Goal in Japan PIII Study: Astellas
February 4, 2026
- Astellas Kicks Off Japan PIII Studies for Hot Flash Med
March 5, 2024
BUSINESS
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Sawai to Drop 46 Generic Products, Takata 30
August 17, 2026
- Healios to File MultiStem in Japan Without Waiting for PIII Results: CEO
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…